Literature DB >> 28715523

Pembrolizumab for Recurrent Conjunctival Melanoma.

Ashwini Kini1, Roxana Fu1, Christopher Compton1, Donald M Miller1, Aparna Ramasubramanian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28715523     DOI： 10.1001/jamaophthalmol.2017.2279

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  9 in total

Review 1.  Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.

Authors:  Anastasia Gkiala; Sotiria Palioura
Journal:  Clin Ophthalmol       Date:  2020-10-09

2.  Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.

Authors:  Oded Sagiv; Sudip D Thakar; Thomas J Kandl; Joshua Ford; Matthew C Sniegowski; Wen-Jen Hwu; Bita Esmaeli
Journal:  JAMA Ophthalmol       Date:  2018-11-01       Impact factor: 7.389

3.  Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Authors:  Jonathan E Lu; Jessica R Chang; Jesse L Berry; Gino K In; Sandy Zhang-Nunes
Journal:  Int Ophthalmol Clin       Date:  2020

4.  Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.

Authors:  Bennett Yau-Bun Hong; Joshua R Ford; Isabella C Glitza; Carlos A Torres Cabala; Michael Tetzlaff; Victor G Prieto; Richard Parker; Claire Daniel; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 Jan-Feb 01       Impact factor: 2.011

5.  Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma.

Authors:  Huan Luo; Chao Ma; Jinping Shao; Jing Cao
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

6.  Efficacy of immune checkpoint inhibitors in different types of melanoma.

Authors:  Ernesto Rossi; Giovanni Schinzari; Brigida Anna Maiorano; Giulia Indellicati; Alessandro Di Stefani; Monica Maria Pagliara; Simona Maria Fragomeni; Erika Valentina De Luca; Maria Grazia Sammarco; Giorgia Garganese; Jacopo Galli; Maria Antonietta Blasi; Gaetano Paludetti; Giovanni Scambia; Ketty Peris; Giampaolo Tortora
Journal:  Hum Vaccin Immunother       Date:  2020-07-14       Impact factor: 3.452

7.  PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome.

Authors:  Sandra Lassalle; Sacha Nahon-Esteve; Eric Frouin; Camille Boulagnon-Rombi; Nicolas Josselin; Nathalie Cassoux; Raymond Barnhill; Boris Scheller; Stéphanie Baillif; Paul Hofman
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

Review 8.  New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.

Authors:  Jennifer Peil; Felix Bock; Friedemann Kiefer; Rebecca Schmidt; Ludwig M Heindl; Claus Cursiefen; Simona L Schlereth
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

Review 9.  Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.

Authors:  Ho-Seok Sa; Claire Daniel; Bita Esmaeli
Journal:  J Ophthalmic Vis Res       Date:  2022-08-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.